Prevention trumps treatment of antibody-mediated transplant rejection

Journal of Clinical Investigation

Volumn 120, Issue 4, 2010, Pages 1036-1039

  Knechtle, Stuart J ^a   Kwun, Jean ^a   Iwakoshi, Neal ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIBODY; CYCLOSPORIN;

ACUTE GRAFT REJECTION; B LYMPHOCYTE; CHRONIC GRAFT REJECTION; GRAFT REJECTION; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONGEVITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; ANTIGENS, CD20; B-LYMPHOCYTES; GRAFT REJECTION; HUMANS; ISOANTIBODIES; LYMPHOCYTE DEPLETION; MACACA FASCICULARIS;

EID: 77951192989     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42532     Document Type: Note

References (18)

1. Terasaki PI. Humoral theory of transplantation. Am J Transplant. 2003;3(6):665-673.
2. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation. 2008;86(3):377-383.
3. Everly MJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant. 2009;9(5):1063-1071.
4. Ramos EJ, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant. 2007;7(2):402-407.
5. Zarkhin V, et al. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant. 2008;8(12):2607-2617.
6. Kamar N, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant. 2010;10(1):89-98.
7. + B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J Clin Invest. 2010;120(4):1275-1284.
8. Teeling JL, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371.
9. Pescovitz MD, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143-2152.
10. Hale DA, Dhanireddy K, Bruno D, Kirk AD. Induction of transplantation tolerance in non-human primate preclinical models. Philos Trans R Soc Lond B Biol Sci. 2005;360(1461):1723-1737.
11. Knechtle SJ, Hamawy MM, Hu H, Fechner JH Jr, Cho CS. Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev. 2001;183:205-213.
12. Sacks S, Lee Q, Wong W, Zhou W. The role of complement in regulating the alloresponse. Curr Opin Organ Transplant. 2009;14(1):10-15.
13. Walters S, et al. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol. 2009;182(2):793-801.
14. Bloom D, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant. 2009;9(8):1835-1845.
15. Larsen CP, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443-453.
16. Li Y, Ma L, Yin D, Shen J, Chong AS. Long-term control of alloreactive B cell responses by the suppression of T cell help. J Immunol. 2008;180(9):6077-6084.
17. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307-328.
18. Ferguson SE, Han S, Kelsoe G, Thompson CB. CD28 is required for germinal center formation. J Immunol. 1996;156(12):4576-4581.